SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-14-004532
Filing Date
2014-10-27
Accepted
2014-10-27 08:52:49
Documents
7
Period of Report
2014-10-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ctic-8k_20141022.htm 8-K 58331
2 EX-3.1 ctic-ex3_2014102288.htm EX-3 96481
3 EX-4.1 ctic-ex4_2014102289.htm EX-4 13306
4 EX-10.1 ctic-ex10_2014102290.htm EX-10 104831
5 EX-10.2 ctic-ex10_2014102291.htm EX-10 40861
6 EX-99.1 ctic-ex99_2014102292.htm EX-99 19323
7 GRAPHIC g201410261650172261.jpg GRAPHIC 9889
  Complete submission text file 0001564590-14-004532.txt   348406
Mailing Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: WA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12465 | Film No.: 141173600
SIC: 2834 Pharmaceutical Preparations